Kura Oncology, Inc. (KURA) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a research report sent to investors on Saturday. They currently have $7.75 price target on the stock.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Other equities analysts also recently issued research reports about the stock. Oppenheimer Holdings, Inc. set a $16.00 price target on shares of Kura Oncology and gave the stock a buy rating in a report on Wednesday, June 14th. Cann reiterated a buy rating and issued a $16.00 price target on shares of Kura Oncology in a report on Monday, May 15th. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the stock a buy rating in a report on Tuesday, August 8th. ValuEngine upgraded shares of Kura Oncology from a sell rating to a hold rating in a report on Friday. Finally, Leerink Swann reiterated an outperform rating and issued a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $14.15.

Shares of Kura Oncology (NASDAQ KURA) opened at 11.65 on Friday. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80. The company’s 50-day moving average is $7.97 and its 200 day moving average is $8.71. The company’s market capitalization is $232.86 million.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities research analysts anticipate that Kura Oncology will post ($1.53) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Upgraded at Zacks Investment Research” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/12/kura-oncology-inc-kura-upgraded-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently modified their holdings of KURA. State of Wisconsin Investment Board acquired a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $102,000. Oppenheimer & Co. Inc. grew its stake in shares of Kura Oncology by 14.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after purchasing an additional 1,600 shares during the period. Segantii Capital Management Ltd acquired a new stake in shares of Kura Oncology during the 1st quarter worth approximately $120,000. Rhumbline Advisers acquired a new stake in shares of Kura Oncology during the 2nd quarter worth approximately $131,000. Finally, Nationwide Fund Advisors acquired a new stake in shares of Kura Oncology during the 1st quarter worth approximately $136,000. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply